6.56  -0.32 (-4.65%)		09-30 16:00
Open: 6.56 High: 7 Volume: 107,460		Pre. Close: 6.88 Low: 6.56 Market Cap: 3(M)

Short term
Mid term
Targets	6-month :	16.72	1-year :	23.76
Resists	First :	14.31	Second :	20.35
Pivot price	7.73
Supports	First :	4.55	Second :	3.79
MAs	MA(5) :	7.32	MA(20) :	8.65
	MA(100) :	13.43	MA(250) :	23.19
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	24.9	D(3) :	24
RSI	RSI(14): 44.7
52-week	High :	80.69	Low :	4.55

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIAF ] has closed above bottom band by 22.7%. Bollinger Bands are 48.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	7.01 - 7.06	7.06 - 7.1
Low:	6.45 - 6.51	6.51 - 6.55
Close:	6.48 - 6.57	6.57 - 6.64

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Wed, 30 Sep 2026
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL - BioSpace

Tue, 29 Sep 2026
Shares could be offered up to 35% below market; bioAffinity Technologies (BIAF) seeks a stockholder vote. - Stock Titan

Thu, 24 Sep 2026
Price to book forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView

Thu, 24 Sep 2026
BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Chart - ChartMill

Tue, 22 Sep 2026
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance Singapore

Tue, 22 Sep 2026
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance Australia

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	1 (M)
Held by Insiders	532260 (%)
Held by Institutions	1.5 (%)
Shares Short	35 (K)
Shares Short P.Month	0 (K)

EPS	-1.197e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-257.4 %
Operating Margin	-220.8 %
Return on Assets (ttm)	-125.2 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	5.9e+006 %
Gross Profit (p.s.)	0.29
Sales Per Share	0.9
EBITDA (p.s.)	-1.77
Qtrly Earnings Growth	-1.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	7.27
Price to Cash Flow	-0.89

Dividend	0
Forward Dividend	13040
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.